{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T04:57:17Z","timestamp":1785473837032,"version":"3.56.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,14]]},"DOI":"10.7759\/cureus.50507","type":"journal-article","created":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T12:17:57Z","timestamp":1702556277000},"source":"Crossref","is-referenced-by-count":3,"title":["Implementation of the Treat-to-Target Approach in Psoriatic Arthritis and Its Outcomes in Routine Clinical Practice"],"prefix":"10.7759","author":[{"given":"Shamas U","family":"Din","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Ahmed","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad R","family":"Hameed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Aamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umbreen","family":"Arshad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafiz Yasir","family":"Qamar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10235659","article-title":"Implementation of the treat-to-target concept in evaluation of psoriatic arthritis patients","volume":"10","author":"Gazitt T","year":"2021","unstructured":"Gazitt T, Elhija MA, Haddad A, Lavi I, Elias M, Zisman D. Implementation of the treat-to-target concept in evaluation of psoriatic arthritis patients. J Clin Med. 2021, 10:5659. 10.3390\/jcm10235659","journal-title":"J Clin Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin CT","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017, 376:957-70. 10.1056\/NEJMra1505557","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.180267","article-title":"What should be the primary target of \"treat to target\" in psoriatic arthritis?","volume":"46","author":"Coates LC","year":"2019","unstructured":"Coates LC, Lubrano E, Perrotta FM, Emery P, Conaghan PG, Helliwell PS. What should be the primary target of \"treat to target\" in psoriatic arthritis?. J Rheumatol. 2019, 46:38-42. 10.3899\/jrheum.180267","journal-title":"J Rheumatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00347-5","article-title":"Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial","volume":"386","author":"Coates LC","year":"2015","unstructured":"Coates LC, Moverley AR, McParland L, et al.. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet. 2015, 386:2489-98. 10.1016\/S0140-6736(15)00347-5","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208337","article-title":"European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update","volume":"75","author":"Gossec L","year":"2016","unstructured":"Gossec L, Smolen JS, Ramiro S, et al.. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016, 75:499-510. 10.1136\/annrheumdis-2015-208337","journal-title":"Ann Rheum Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates LC","year":"2022","unstructured":"Coates LC, Soriano ER, Corp N, et al.. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022, 18:465-79. 10.1038\/s41584-022-00798-0","journal-title":"Nat Rev Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-eular.5634","article-title":"THU0288\u2005Implementation of the treat to target concept in evaluation of psoriatic arthritis patients","volume":"77","author":"Abu Elhija M","year":"2018","unstructured":"Abu Elhija M, Haddad A, Lavi I, Gazitt T, Zisman D. THU0288\u2005Implementation of the treat to target concept in evaluation of psoriatic arthritis patients. Ann Rheum Dis. 2018, 77:362-3. 10.1136\/annrheumdis-2018-eular.5634","journal-title":"Ann Rheum Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2012.121","article-title":"Spondyloarthritis: CASPAR criteria in early psoriatic arthritis","volume":"8","author":"Chandran V","year":"2012","unstructured":"Chandran V. Spondyloarthritis: CASPAR criteria in early psoriatic arthritis. Nat Rev Rheumatol. 2012, 8:503-4. 10.1038\/nrrheum.2012.121","journal-title":"Nat Rev Rheumatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2004.05697.x","article-title":"Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis","volume":"150","author":"Feldman SR","year":"2004","unstructured":"Feldman SR, Menter A, Koo JY. Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis. Br J Dermatol. 2004, 150:317-26. 10.1111\/j.1365-2133.2004.05697.x","journal-title":"Br J Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-018-0132-4","article-title":"Assessing disease activity in psoriatic arthritis: a literature review","volume":"6","author":"Tucker LJ","year":"2019","unstructured":"Tucker LJ, Coates LC, Helliwell PS. Assessing disease activity in psoriatic arthritis: a literature review. Rheumatol Ther. 2019, 6:23-32. 10.1007\/s40744-018-0132-4","journal-title":"Rheumatol Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22576","article-title":"Radiographic progression of patients with psoriatic arthritis who achieve minimal disease activity in response to golimumab therapy: results through 5 years of a randomized, placebo-controlled study","volume":"68","author":"Kavanaugh A","year":"2016","unstructured":"Kavanaugh A, van der Heijde D, Beutler A, et al.. Radiographic progression of patients with psoriatic arthritis who achieve minimal disease activity in response to golimumab therapy: results through 5 years of a randomized, placebo-controlled study. Arthritis Care Res (Hoboken). 2016, 68:267-74. 10.1002\/acr.22576","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-eular.2217","article-title":"Are we treating-to-target in spondyloarthritis (SpA)? A cross sectional analysis from the Asia Pacific League of Associations for Rheumatology (APLAR) SpA Registry","volume":"81","author":"Cheng IT","year":"2022","unstructured":"Cheng IT, So H, Leung YY, et al.. Are we treating-to-target in spondyloarthritis (SpA)? A cross sectional analysis from the Asia Pacific League of Associations for Rheumatology (APLAR) SpA Registry. Ann Rheum Dis. 2022, 81:1506-7. 10.1136\/annrheumdis-2022-eular.2217","journal-title":"Ann Rheum Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001083","article-title":"Treat-to-target in PsA: methods and necessity","volume":"6","author":"Dures E","year":"2020","unstructured":"Dures E, Shepperd S, Mukherjee S, Robson J, Vlaev I, Walsh N, Coates LC. Treat-to-target in PsA: methods and necessity. RMD Open. 2020, 6:e001083. 10.1136\/rmdopen-2019-001083","journal-title":"RMD Open"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/art.40391","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis\/Outcome Measures in Rheumatology consensus-based recommendations and research agenda for use of composite measures and treatment targets in psoriatic arthritis","volume":"70","author":"Coates LC","year":"2018","unstructured":"Coates LC, FitzGerald O, Merola JF, et al.. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis\/Outcome Measures in Rheumatology consensus-based recommendations and research agenda for use of composite measures and treatment targets in psoriatic arthritis. Arthritis Rheumatol. 2018, 70:345-55. 10.1002\/art.40391","journal-title":"Arthritis Rheumatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23569","article-title":"Does systemic lupus erythematosus care provided in a lupus clinic result in higher quality of care than that provided in a general rheumatology clinic?","volume":"70","author":"Arora S","year":"2018","unstructured":"Arora S, Nika A, Trupin L, et al.. Does systemic lupus erythematosus care provided in a lupus clinic result in higher quality of care than that provided in a general rheumatology clinic?. Arthritis Care Res (Hoboken). 2018, 70:1771-7. 10.1002\/acr.23569","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/206482-implementation-of-the-treat-to-target-approach-in-psoriatic-arthritis-and-its-outcomes-in-routine-clinical-practice","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:09:51Z","timestamp":1707509391000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/206482-implementation-of-the-treat-to-target-approach-in-psoriatic-arthritis-and-its-outcomes-in-routine-clinical-practice"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,14]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.50507","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,14]]}}}